Differences in the baseline characteristics among the patients receiving different baseline DMARD co-therapies were found (table 1).
There were no significant differences in the baseline characteristics between the two groups.
It should be noted that there were differences in the baseline periods for model calibration between these studies and ours, and that ref.86 focused only on near-surface permafrost within 3 meters of the surface.
Analyses of previous trials demonstrate profound differences in the baseline characteristics of patients enrolled across global regions and participating sites.
This allows for year-to-year differences in the baseline hazard curve (Cleves et al. 2008).
As shown in Table 1, due to the retrospective design of our study, some differences in the baseline characteristics occurred.
Likewise, we did not observe significant differences in the baseline scores of the assessed scales, except the TSK, which was significantly higher in the HA group.
There were no statistically significant differences in the baseline demographic and clinical characteristics between the 2 non-responder groups (Table 1).
We analyzed the differences in the baseline task performance between both groups and whether the outcome was related with baseline prefrontal functioning.
We sought to determine variation in the rates and differences in the baseline characteristics and clinical outcomes between AIS cases presenting directly to stroke centers' front door versus Transfer-Ins from another hospital.
CONCLUSIONS These results suggest that strain-specific changes in chromatin and transcription in response to chemical exposure lead to a "compensation" for underlying genetic-driven interindividual differences in the baseline chromatin and transcriptional state.
